THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | RU |
| Publicado: |
SPb RAACI
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8e38443b3d374402a828da8b3562db73 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8e38443b3d374402a828da8b3562db73 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8e38443b3d374402a828da8b3562db732021-11-18T08:03:47ZTHE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY1563-06252313-741X10.15789/1563-0625-2018-5-667-680https://doaj.org/article/8e38443b3d374402a828da8b3562db732018-11-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1635https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XChemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of the tumor cells and to influence anti-tumor immune response. Initial state of the immune system and its response to treatment is crucial. Antitumor response involves cells of innate and adaptive immunity (NK, NKT, T cells). These populations are heterogeneous and contain, e.g., cells with antitumor activity and regulatory (suppressor) cells that suppress immune response and promote tumor progression. The aim of this work was to determine the relationship between the initial state of cellular immunity of patients suffering from locally advanced breast cancer with triple negative phenotype, and clinical effect of chemotherapy (cisplatin + doxorubicin/paclitaxel), and studying effects of the therapy upon subpopulation profiles of peripheral blood lymphocytes in the patients. We registered the terms of the disease progression as well as overall survival and progression-free survival. The disease progressed in 25 of 53 cases (47.2%) whereas 28 of 53 patients (52.8%) remained progression-free. The observation period was 35.5 months. Laboratory examination of the patients included immunophenotyping of peripheral blood lymphocytes and determination of NK cell cytotoxic activity before and after chemotherapy. Percentages of effectors and regulatory lymphocyte populations were determined. The results obtained showed that, for some lymphocyte subsets, the pre-treatment differences of cell percentage deviations from control were found between the progression-free groups and patients with progression of the disease. The differences in percentages of NKT cells and lymphocytes expressing CD25 activation marker proved to be most significant. Decreased number of NKT cells and activated CD25+ lymphocytes prior to chemotherapy was associated with increased probability of disease progression. Reduced percentage of NKT cells against control was observed in 56% of patients from the progression group (PD), and only 21.4% in the group free of disease progression (DF). [OR = 4.6 (95% CI 1.4 to 15.4)]. Percentage of CD25+ lymphocytes was decreased from 68.2% in the PD group, and 28.6% for DF patients [OR = 5.4 (95% CI 1.6-18.1)]. We studied relationships between the overall survival (OS) and percentage of perforin-containing NK, NKT, and T cells, and mean perforin fluorescence density (PFD) in these lymphocyte subsets in 26 of the 53 patients before treatment. A statistically significant positive correlation was revealed between OS and perforin PFD in all the three cell populations under study. Normalization of the parameters altered before treatment, and an increase of T cell numbers was observed in the disease-free patients.A. I. ChertkovaE. G. SlavinaE. K. ShouaL. G. ZhukovaM. A. OkruzhnovaV. A. NurtdinovaA. A. BorunovaN. Т. DzhgamadzeZ. G. KadagidzeSPb RAACIarticletriple negative breast cancerchemotherapyperipheral lymphocyte subpopulationsdisease progressionoverall survivalprogression-free survivalImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 20, Iss 5, Pp 667-680 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
RU |
| topic |
triple negative breast cancer chemotherapy peripheral lymphocyte subpopulations disease progression overall survival progression-free survival Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
triple negative breast cancer chemotherapy peripheral lymphocyte subpopulations disease progression overall survival progression-free survival Immunologic diseases. Allergy RC581-607 A. I. Chertkova E. G. Slavina E. K. Shoua L. G. Zhukova M. A. Okruzhnova V. A. Nurtdinova A. A. Borunova N. Т. Dzhgamadze Z. G. Kadagidze THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| description |
Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of the tumor cells and to influence anti-tumor immune response. Initial state of the immune system and its response to treatment is crucial. Antitumor response involves cells of innate and adaptive immunity (NK, NKT, T cells). These populations are heterogeneous and contain, e.g., cells with antitumor activity and regulatory (suppressor) cells that suppress immune response and promote tumor progression. The aim of this work was to determine the relationship between the initial state of cellular immunity of patients suffering from locally advanced breast cancer with triple negative phenotype, and clinical effect of chemotherapy (cisplatin + doxorubicin/paclitaxel), and studying effects of the therapy upon subpopulation profiles of peripheral blood lymphocytes in the patients. We registered the terms of the disease progression as well as overall survival and progression-free survival. The disease progressed in 25 of 53 cases (47.2%) whereas 28 of 53 patients (52.8%) remained progression-free. The observation period was 35.5 months. Laboratory examination of the patients included immunophenotyping of peripheral blood lymphocytes and determination of NK cell cytotoxic activity before and after chemotherapy. Percentages of effectors and regulatory lymphocyte populations were determined. The results obtained showed that, for some lymphocyte subsets, the pre-treatment differences of cell percentage deviations from control were found between the progression-free groups and patients with progression of the disease. The differences in percentages of NKT cells and lymphocytes expressing CD25 activation marker proved to be most significant. Decreased number of NKT cells and activated CD25+ lymphocytes prior to chemotherapy was associated with increased probability of disease progression. Reduced percentage of NKT cells against control was observed in 56% of patients from the progression group (PD), and only 21.4% in the group free of disease progression (DF). [OR = 4.6 (95% CI 1.4 to 15.4)]. Percentage of CD25+ lymphocytes was decreased from 68.2% in the PD group, and 28.6% for DF patients [OR = 5.4 (95% CI 1.6-18.1)]. We studied relationships between the overall survival (OS) and percentage of perforin-containing NK, NKT, and T cells, and mean perforin fluorescence density (PFD) in these lymphocyte subsets in 26 of the 53 patients before treatment. A statistically significant positive correlation was revealed between OS and perforin PFD in all the three cell populations under study. Normalization of the parameters altered before treatment, and an increase of T cell numbers was observed in the disease-free patients. |
| format |
article |
| author |
A. I. Chertkova E. G. Slavina E. K. Shoua L. G. Zhukova M. A. Okruzhnova V. A. Nurtdinova A. A. Borunova N. Т. Dzhgamadze Z. G. Kadagidze |
| author_facet |
A. I. Chertkova E. G. Slavina E. K. Shoua L. G. Zhukova M. A. Okruzhnova V. A. Nurtdinova A. A. Borunova N. Т. Dzhgamadze Z. G. Kadagidze |
| author_sort |
A. I. Chertkova |
| title |
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| title_short |
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| title_full |
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| title_fullStr |
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| title_full_unstemmed |
THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY |
| title_sort |
main parameters of cellular immunity in patients with triple-negative breast cancer: relationship with efficiency of chemotherapy |
| publisher |
SPb RAACI |
| publishDate |
2018 |
| url |
https://doaj.org/article/8e38443b3d374402a828da8b3562db73 |
| work_keys_str_mv |
AT aichertkova themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT egslavina themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT ekshoua themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT lgzhukova themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT maokruzhnova themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT vanurtdinova themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT aaborunova themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT ntdzhgamadze themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT zgkadagidze themainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT aichertkova mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT egslavina mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT ekshoua mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT lgzhukova mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT maokruzhnova mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT vanurtdinova mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT aaborunova mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT ntdzhgamadze mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy AT zgkadagidze mainparametersofcellularimmunityinpatientswithtriplenegativebreastcancerrelationshipwithefficiencyofchemotherapy |
| _version_ |
1718422365398892544 |